Latest ebit for HYL.BR: $-8.1M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2025
Trailing 12 months ending Dec 31, 2025
The latest EBIT for HYL.BR is $-8.1M as of December 2025. That compares with $-6.1M in the prior-year period — down 34.0% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Hyloris Pharmaceuticals S.A.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, HYL.BR's EBIT moved from $-6.1M to $-8.1M — a 34.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hyloris Pharmaceuticals S.A.'s operating scale or balance-sheet position.
Against Healthcare companies, HYL.BR currently prints $-8.1M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Hyloris Pharmaceuticals S.A.'s growth, margins, and balance sheet.
A EBIT figure of $-8.1M for HYL.BR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.
After noting HYL.BR's EBIT ($-8.1M), review year-over-year change from $-6.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.